Immunitas Therapeutics Launches with $39 Million Series A to Advance Lead Programs to Human Efficacy Studies Based on a Unique Human Immunology-Focused Drug Development Platform


  • Kai Wucherpfennig M.D., Ph.D., Mario Suvà M.D., Ph.D., and Dane Wittrup, Ph.D. are among Scientific Founders


Boston, MA, USA, 21 November 2019:
Immunitas Therapeutics (“Immunitas”), a single cell genomics-based drug discovery company founded by Longwood Fund, today announced a $39 million Series A financing led by Leaps by Bayer and Novartis Venture Fund and joined by additional investors including Evotec, M Ventures, Alexandria Venture Investments, and other institutional investors. The company plans to use this funding to advance its first programs, monoclonal antibody therapeutics with single agent activity in preclinical models of oncology, to clinical studies.

For the full version of the press release by Immunitas, please follow this link.



Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.